Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature

MeSH terms

• Aged
• Allografts
• Anemia, Refractory, with Excess of Blasts / physiopathology
• Aniline Compounds / administration & dosage
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Azacitidine / administration & dosage
• Breast Neoplasms / radiotherapy
• Breast Neoplasms / surgery
• Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
• Clinical Trials, Phase III as Topic
• Cytarabine / administration & dosage
• Daunorubicin / administration & dosage
• Fatal Outcome
• Female
• Humans
• Leukemia, Myeloid, Acute / drug therapy*
• Leukemia, Myeloid, Acute / etiology
• Leukemia, Myeloid, Acute / genetics
• Leukemia, Myeloid, Acute / pathology
• Liposomes
• Male
• Middle Aged
• Myelodysplastic Syndromes / physiopathology
• Neoplasm, Residual
• Neoplasms, Radiation-Induced / drug therapy
• Neoplasms, Radiation-Induced / genetics
• Neoplasms, Radiation-Induced / mortality
• Neoplasms, Radiation-Induced / pathology
• Oncogene Proteins, Fusion / antagonists & inhibitors
• Oncogene Proteins, Fusion / genetics
• Peripheral Blood Stem Cell Transplantation
• Point Mutation
• Protein Kinase Inhibitors / administration & dosage
• Pyrazines / administration & dosage
• Remission Induction
• Salvage Therapy
• Staurosporine / administration & dosage
• Staurosporine / analogs & derivatives
• Sulfonamides / administration & dosage
• fms-Like Tyrosine Kinase 3 / antagonists & inhibitors
• fms-Like Tyrosine Kinase 3 / genetics*